The first cord blood transplantation (CBT) was performed in a 5-year-old boy with acute mylogenous leukemia from his HLA-identical sibling donor in 1994. Since then there have been 17 related and 131 unrelated CBTs in Japan. Overall survival and disease-free survival (DFS) were over 70% in sibling donor CBT. DFS of unrelated CBT in leukemia and other hematological malignancies was 43%, and OS of UCBT in non-malignant diseases was 63%. HLA disparity between the donor and the recipient did not affect the incidence and severity of acute graft-versus-host disease (GVHD) or survival. Cell dose was the most important factor for engraftment and survival both in malignant and in nonmalignant diseases. The Japanese government has recently established the nationwide cord blood bank network, and eight local cord blood banks are financially supported by the government. 20 000 units of CB are planned to be collected and stored in the next 5 years by this network. Bone Marrow Transplantation (2000) 25, Suppl. 2, S68-S70.
Summary:
The first cord blood transplantation (CBT) was performed in a 5-year-old boy with acute mylogenous leukemia from his HLA-identical sibling donor in 1994. Since then there have been 17 related and 131 unrelated CBTs in Japan. Overall survival and disease-free survival (DFS) were over 70% in sibling donor CBT. DFS of unrelated CBT in leukemia and other hematological malignancies was 43%, and OS of UCBT in non-malignant diseases was 63%. HLA disparity between the donor and the recipient did not affect the incidence and severity of acute graft-versus-host disease (GVHD) or survival. Cell dose was the most important factor for engraftment and survival both in malignant and in nonmalignant diseases. The Japanese government has recently established the nationwide cord blood bank network, and eight local cord blood banks are financially supported by the government. 20 000 units of CB are planned to be collected and stored in the next 5 years by this network. Bone Marrow Transplantation (2000) 25, Suppl. 2, S68-S70. Keywords: cord blood transplantation; cord blood bank; HLA; GVHD; Japan Hematopoietic potential of cord blood cells was first reported by Nakahata and Ogawa 1 in 1982. Since then many researchers have extended hematological and immunological characteristics of cord blood cells. The first successful CBT in a boy with Fanconi's anemia was reported by Gluckman et al 2 in 1989 . The first CBT in Japan was performed in a 5-year-old boy with refractory AML in 1994 and was reported in 1996. 3 The number of CBT from sibling donors increased gradually in the early 1990s and several features of CBT were clarified. Two main characteristics of CBT are hematological reconstitution by a small number of nucleated cells and mild GVHD, which allows HLA mismatches between the donor and the recipient.
Cord blood banking was started by Rubinstein in 1992, and more than 1000 unrelated CBTs have been done by many groups in the world up to 1999. 4 Transplanted cell
Correspondence: Dr S Kato, Department of Pediatrics, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa, 259-1193, Japan dose was reported to be most important in the unrelated setting, and HLA disparity has not been reported to affect the outcome of UCBT. We report the current status of cord blood transplantation and cord blood banking in Japan.
Patients and methods

Data collection
Several national surveys have been conducted by two research grants from the Ministry of Health and Welfare (Chairmen; Y Kodera and H Saito). Data collected included disease, age, weight, serological HLA types of each patient, birth weight, volume of aspirated cord blood and serological HLA types of each donor, processing and the number of cells collected and transplanted, methods of conditioning, GVHD prophylaxis and transplant outcome. Recovery of immune function was serially examined in four sibling donor CB recipients and seven unrelated CB recipients, and was compared with those in sibling donor BMT and unrelated donor BMT.
Patients and donors
A total of 148 patients with leukemia, other hematological malignancies, bone marrow failure, congenital immunodeficiencies, inborn error of metabolism and some other fatal disorders received CBT from related or unrelated donors. Their ages ranged from 0 to 49 years, and their weights ranged from 6 to 69 kg. Seventeen related and 131 unrelated newborn babies served as donors. HLA antigens were identical in 14 cases, 1 antigen mismatched in one, 2 antigens mismatched in one and 3 antigens mismatched in two cases who were transplanted from sibling donors, whereas there were 0 mismatch in five, 1 mismatch in 76 and 2 mismatches in 24 cases.
Conditioning and GVHD prophylaxis
Conditioning and GVHD prophylaxis varied from center to center and from patient to patient in each center. 
Results
Related donor CBT
Engraftment of donor cord blood was achieved in 17 out of 18 cases. Acute GVHD was grade 0 in seven cases, grade I in five cases, grade II in three cases and grade III in two cases. Overall survival was 77.0% and DFS was 71.8% at 28 months post transplantation. 5 
Unrelated donor CBT
Engraftment of donor cord blood was achieved in 108 out of 131 cases. Acute GVHD was grade 0 in 42 cases, grade I in 22 cases, grade II in 25 cases, grade III in 15 cases, grade IV in four cases and not evaluable due to early death or too short follow-up. DFS of UCBT in leukemia and other hematological malignancies was 43%, and overall survival of UCBT in non-malignant diseases was 63%.
HLA was not correlated with the incidence of acute GVHD or survival. Cell numbers per kilogram of patient's body weight was correlated with the speed and rate of donor engraftment and with survival rate both in malignant and in non-malignant diseases.
Age and body weight of the patients also affected the engraftment and survival. Younger and lighter patients survived better than older and heavier patients.
Comparison of engraftment between sibling donor CBT and UCBT
Total nucleated cell number, CD34-positive cell number and CFU-GM did not differ between the two groups. Neutrophil recovery was not different between the two groups, but reticulocyte and platelet recoveries were delayed in UCBT than in sibling CBT.
Bone Marrow Transplantation
Immune recovery after transplantation IL-2 response was lower in total CBT recipients than in total BMT recipients, but it was not different between HLA matched sibling BMT and HLA matched sibling CBT. The response was lower in unrelated CBT recipients than in sibling CBT recipients.
Discussion
The results of related and unrelated CBT in Japan are comparable with previous reports by others. 4, [6] [7] [8] HLA haploidentical transplantation is feasible from sibling donors, and the minimum nucleated cell number needed for donor engraftment seems to be 10 millions per kilogram. Although cell recovery, especially platelet recovery, is more markedly delayed than in BMT, the final donor engraftment rate does not differ from that of BMT. HLA disparity seems to affect severity of acute and chronic GVHD in related CBT.
In contrast, the minimum nucleated cell number in unrelated CBT seems to be higher than in related CBT. Twenty million per kilogram might be the lower limit for donor engraftment. Cell dose was correlated with engraftment and survival. Age and weight were also correlated with engraftment and survival, probably secondary due to cell number per kilogram. HLA disparity, however, did not affect the severity or survival. Two HLA antigens mismatched recipients had a similar incidence of severe acute GVHD and survival rate to 0 or 1 antigen mismatched recipients.
These encouraging data have promoted the establishment and the extension of cord blood banks in many countries. The Japanese Ministry of Health and Welfare has recently decided to provide a budget for the establishment of a cord blood bank network, and the Japan Cord Blood Bank Network has started its activity in 1999 (Figure 1 ). Eight local cord blood banks were selected and are financially supported by the government.
